The ROS1 Cancer Model Project: a unique patient-driven partnership to accelerate research

Amy C. Moore1, Lisa Goldman2, Tori Tomalia2, Robert C. Doebele3, Christine M. Lovly4, Rachel Chiparelli5, Tony Addario6, Bonne J. Addario1, Janet Freeman-Daly7

1GO2 Foundation for Lung Cancer, San Carlos, CA, 2The ROS1ders Inc., Mountain View, CA, 3University of Colorado Denver, Aurora, CO, 4Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, 5Champions Oncology Inc., Hackensack, NJ, 6Addario Lung Cancer Medical Institute, San Carlos, CA

INTRODUCTION

Motivated, Engaged ROS1+ Online Community

Facebook group: • ROS1 Positive (ROS1+) Cancer
Facebook Page: ROS1 Cancer Research Forum
ROS1cancer.com
• List of ROS1+ expert clinicians
• Living with ROS1+ cancer
• Drugs with ROS1 activity
• Clinical trials for ROS1 patients
Twitter: @ros1cancer, #ROS1

GLOBAL ROS1 INITIATIVE CONTACT
ROS1cancer.patient@gmail.com

Pan-Cancer Challenges of ROS1 Rearrangements

Other Tumors Can Harbor ROS1+
- angiosarcoma
- breast cancer
- cervical cancer
- cholangiocarcinoma
- colon cancer
- epithelial hemangioidotheliomas
- gastric cancer
- glioblastoma
- inflammatory myofibroblastic tumor
- liver cancer
- melanoma
- ovarian cancer
- pancreatic cancer

To date we have created 8 new cell lines (which doubled the available ROS1 cancer lines) and initiated 5 PDX mouse models. These cell lines have been genomically characterized (ROS1-CD74, one ROS1-TPM3). The cell lines have been shared with five other institutions researching ROS1 cancers: UCSF, Huntsman Cancer Institute, NIH, Moffitt Cancer Center, and IJtlip (now Roche). The cell lines have been used in three published ROS1 journal articles, among them an analysis of ROS1 resistance mechanisms to targeted therapies (left).

METHODS

Collect Patient Medical Records & Specimens
Model Creation, Analysis, Data Interpretation
Dissemination of Annotated ROS1+ Models

THE PATIENT VOICE

"The ROS1 Cancer Model Project, part of the larger Global ROS1 Initiative, has the potential to powerfully impact cancer research. Patients organizing and collaborating with researchers in this manner is the future."

"The Global Initiative is a way we can contribute to research in hopes of helping others with this rare cancer."

CONCLUSIONS

The ROS1 Cancer Model Project is part of the Global ROS1 Initiative, a powerful partnership between patients & caregivers, advocacy organizations, researchers and industry that, when combined with social media outreach, has increased the available oncogene-driven patient data, specimens, and cancer models for rare, geographically-distributed pan-cancer patient populations. Current efforts are focused on growing the number of models available and disseminating them for research.

STUDY CONTACT

+1 (866) 988-ROS1
ClinicalOps@ALCMI.net
https://alcmi.net/research/ros1-pdx-study/

ACKNOWLEDGMENTS

Thanks to all ROS1 clinicians, researchers, patients, caregivers, supporters, and partners who make the ROS1 Cancer Model Project possible. Jeff Wynne collected data for the ROS1der demographics. Funding and in-kind support for the Global ROS1 Initiative is provided by individual ROS1ders, Addario Lung Cancer Medical Institute, GO2 Foundation for Lung Cancer, Champions Oncology, and University of Colorado Lung SPORE.